JJP Biologics

During the panel discussion at SCOPE Europe in Barcelona JJP Biologics Head of Clinical Development perfectly and engaged explained our SMART clinical strategy to support fast development of JJP-1212. With the help of the PM Joanna Mysiak, he managed to obtain approval to execute our, currently ongoing, phase I safety assessment in healthy volunteers. This was all done according to challenging timelines and is the JJP Biologics clinical team is now focused on organising and executing our phase II studies that will start in 2025 for JJP-1212. Other panel members were Diana Andrade and Maria Veleva. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM,#biotechnology, #JJP1212, #SMARTGOOSE

JJP Biologics Senior PM Joanna Mysiak (Asia) presenting her own personal journey and development, but certain also the journey of JJP-1212 at SCOPE Europe in Barcelona. Since Asia has become the PM for JJP-1212 she has solved and mitigated various vendor related risks to control the timelines towards and from the JJP-1212 First-in-Human study. She have shared her real-life experiences and used these examples to illustrate her "SMART GOOSE" strategy how she managed together with her amazing team at JJP Biologics to keep her timelines within budget. JJP-1212 is currently in phase I safety testing and will enter phase II in 2025. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE, #ABM

The JJP Biologics team at SCOPE Europe in Barcelona is getting ready for the real action. On stage Joanna Mysiak and Dawid Łyżwa supported by Anna Łosińska. They will present best practices for mitigating vendor-related risks in first-in-human clinical trials, ensuring safe and efficient drug development. Discover how to implement effective vendor qualification, clear contracting, and a risk-based approach to vendor oversight through real-world case studies. The story about their journey is engaging because they have a final destination. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

Last Friday JJP Biologics Study Physician Dr. Aleksandra Cegiel presented JJP Biologics clinical strategy for our lead antibody JJP-1212 at the: Congress of the Young Forum Section of the Polish Dermatological Society in Łódź, 24-25.10.2024 The title of Dr. Aleksandra Cegiel presentation was entitled: Linear IgA Dermatosis (LAD) - Epidemiology and Development of Anti-CD89 Monoclonal Antibody During the presentation she highlighted the status of our ongoing clinical phase I study, in which we test the safety of JJP-1212 during a SAD followed by a MAD dosing regime. Moreover as seen on the photo's, she also has presented the published proof-of-concept data in LAD, as a bright green fluorescent IgA deposit at the border of the dermis and epidermis adjacent to the red florescence which detects CD89 on neutrophils binding to the IgA. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

IgA in neurology beyond Alzheimer Disease Direct proof that there are systemic autoantibodies of the IgA isotype against myelin basic protein in a patient suffering from Multiple Sclerosis by the group of Prof. Harald Pruss. With CD89-expressing peripheral neutrophils and monocytes that can enter the brain through branches of the BBB at the lesions and CD89 microglia cells as resident immune cells in the CNS, these IgA deposits on MBP will result in activation of these immune cells. The effector functions of these CD89 bearing immune cells cause pathogenic inflammation and damage. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

JJP Biologics is very proud that Prof. Tomasz Grabowski our Head of Preclinical Development was invited to have to opening lecture of the this two day training entitled: "Regulatory pharmacology and pharmacometrics in practice". Moreover, Prof Tomasz Grabowski was chairman of first day of the training. JJP Biologics endorses our specialists to share their experience for the benefit of developing a strong and sustainable Polish biotech sector.

Tomorrow and Wednesday at SCOPE Europe in Barcelona, JJP Biologics Head of Clinical Development Dawid Łyżwa, joined by our Senior Project Manager Joanna Mysiak responsible for the development of JJP-1212, will engage you with their respective real-life journeys establishing the JJP Biologics team and how they established to help the JJP-1212 program progressing into our ongoing SAD and MAD HV phase I study. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #JJP1212 #AntiCD89 #IgA #AgencjaBadańMedycznych #SMARTGOOSE

For people that have listen to presentation of our CSO about the SMART GOOSE story over the last few months, please find below the link to the original document describing the SMART GOOSE story. Be a SMART GOOSE: https://lnkd.in/dFy6C7yP

Our CEO Pawel Szczepanski in full swing during the panel discussion during #LSBC 11th lsbc Central European Life Science Investment Conference in Cracow. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9

An engaging story on Wednesday October 16 at the Festival of Biologics about how to apply JJP Biologics JJP-1212 in various autoimmune and fibrotic diseases. Our CSO, Dr. Louis Boon, highlighted the current early clinical development of JJP-1212 in phase I, the intended PoC in patients suffering from Linear IgA Bullous Disease (a rare dermatological indication) and the much broader applications in Rheumatoid Arthritis and Cystic Fibrosis. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #JJP1008 #SMARTGOOSE